Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "Transgenic Model" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A disease in a transgenic animal with pathologic mechanisms sufficiently similar to those of a human disease for the animal disease to serve as a model.
Detection method for expression of GPR120 gene based on eGFP, and application of eGFP to detection of expression of GPR120 gene
InactiveCN107227352AControl errorReduce the error between groupsMicrobiological testing/measurementVector-based foreign material introductionRNA extractionGPR120
The invention discloses a detection method for the expression of a GPR120 gene based on eGFP. The detection method comprises the following steps: inserting an eGFP fragment to the specific site TAA of the termination codon of the GPR120 gene by using CRISPR / Cas 9 technology so as to obtain a transgenic model mouse with eGFP-labeled GPR120 positive cells; and carrying out excitation by using a fluorescence analyzer and determining the fluorescence intensity of the positive cells of the mouse. The method carries out real-time monitoring on the expression of the GPR120 gene so as to control and reduce errors among groups, guarantee the reliability of results and compensate for and overcome the problems of variability caused by comparison of different groups of histocytes and incapability of monitoring the changes of gene expression at a living cell level in the prior art. According to the invention, the expression level of the GPR120 gene can be immediately determined after collection of cells, and operations and reactions like RNA extraction, inverse transcription and PCR are omitted, so detection of the expression of the GPR120 gene is simpler.
Owner:XIAN MEDICAL UNIV
Ras association domain containing protein
InactiveUS6485910B1Enhanced interactionHigh frequencySugar derivativesPeptide/protein ingredientsAllergyADAMTS Proteins
The invention provides a mammalian cDNA which encodes a mammalian Ras association domain containing protein. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of cell proliferative and inflammatory disorders, particularly thymus hyperplasia, allergies, asthma, and hypereosinophilia. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.
Owner:INCYTE
Transferrin receptor transgenic models
In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
Owner:DENALI THERAPEUTICS INC
Transgenic models of alzheimer's disease and uses therefor in the treatment of a variety of neurodegenerative diseases
In accordance with the present invention, it is demonstrated that selected mutations such as an Asp -> Ala (D664A) mutation in APP (which prevents cleavage at the caspase cleavage site) prevent both hippocampal synaptic loss and dentate gyral atrophy, even though such mutations do not interfere with the production of Ass or the formation of amyloid plaques in a transgenic model of Alzheimer's disease. Accordingly, in view of this finding, methods have been developed for the identification of agents which block cleavage at Asp664 of APP, including transgenic animals which are useful for such purpose, as well as methods for the use thereof for the treatment of neurodegenerative diseases.
Owner:THE BUCK INST FOR RES ON AGING
Construction method and application of humanized mouse model
InactiveCN104046644AMicrobiological testing/measurementVector-based foreign material introductionDiseaseDevelopmental anomaly
The invention relates to a construction method and application of a humanized mouse model, in particular to a construction method and application of a transgenic mouse model of a human Nbs1<c.657del5> gene. The method includes: constructing a 5bp deletion mutation-containing BAC carrier in the human Nbs1 gene, conducting pronuclei microinjection, and performing screening to obtain 3 stable transgenic lines for high expression and low expression of the human Nbs1 gene. The transgenic mouse involved in the invention has the phenotypes of delayed puberty, uniform shortening of body length and bone dysplasia at certain proportion in one of the lines, and a new mouse model is established for Nijmegen breakage syndrome diseases. At the same time, as the Nbs1 gene function impairment is closely related to cancers, the transgenic model can be applied to short-term carcinogenic tests in drug pre-clinical safety evaluation, thus providing a potential substitution model for traditional biennium carcinogenic tests and also providing an effective tool for research of carcinogenesis mechanisms.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Building method of Drosophila melanogaster model for screening and researching mitochondria disease virulence gene, and application of same
The invention provides a building method of a Drosophila melanogaster model for screening and researching mitochondria disease virulence gene, and an application of the same. In the method, first fluorescent protein is represented by a mitochondria in a wing nerve cell in a Drosophila melanogaster model; second fluorescent protein is represented by in a wing nerve cell film in the Drosophila melanogaster model; the mitochondria is labeled via the first fluorescent protein positioned by the mitochondria; the nerve cell is labeled by the second fluorescent protein positioned by the nerve cell film; and research to mitochondria functions in a nervous system can be achieved in vivo. The Drosophila melanogaster transgene model built by the method can simply and conveniently screen and research mitochondria disease virulence genes; and demands for high flux, strong economic property and short time during mitochondria disease virulence gene screening can be met.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
Construction method for transgene mouse model of overexpressing Rps23r1 gene
The invention discloses a construction method for a transgene mouse model of overexpressing an Rps23r1 gene, belonging to transgene models, in particular relating to the construction method for the transgene mouse model of specifically over-expressing the Rps23r1 gene in a brain. A transgene mouse of over-expressing the Rps23r1 gene is obtained through cloning the Rps23r1 gene, constructing a recombinant plasmid and injecting into a germ cell of the mouse. A genome of the transgene mouse of over-expressing the Rps23r1 gene stably integrates the Rps23r1 gene driven by a mouse Prion gene promoter and can be stably inherited to offspring and express an exogenous RPS23R1 protein with an Myc mark in the brain. The Rps23r1 transgene mouse is found not to have abnormal changes in the long-term observation and provides effective means for researching and estimating Rps23r1 physiological and pathologic functions in vivo.
Owner:XIAMEN UNIV
Aquaporin-8 variant
The invention provides a mammalian cDNA which encodes a mammalian AQP8V. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of pancreatic disorders, particularly type I diabetes. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.
Owner:INCYTE
Application of noble dendrobium total alkali in preparing drug for atherosclerosis
InactiveCN108888713AOvercoming background technical difficultiesCardiovascular disorderPlant ingredientsPharmacometricsBiomedicine
The invention discloses an application of noble dendrobium total alkali in preparing a drug for atherosclerosis and belongs to the technical field of biomedicine. According to the application of nobledendrobium total alkali in preparing the drug for atherosclerosis, the noble dendrobium is biennial noble dendrobium and the dosage of the noble dendrobium total alkali is 20-180 mg / kg per day. The invention further explicits the degreasing action of noble dendrobium total alkali DNLA and a probable action mechanism thereof. By adopting an experimental rat atherosclerosis model and an ApoE- / - mouse transgenic model, influence of the DNLA on hyperlipidemia atherosclerosis of blood vessels is observed, and the action mechanism thereof is analyzed, finding that the DNLA has preventing and treating action on the rat atherosclerosis model and the action mechanism is partially related to down-regulation of expression of MCP-1 / CCR2, MCPIP and CRP genes, thereby providing a basic pharmacologicalbasis for clinical treatment of HLP and As by DENLA.
Owner:ZUNYI MEDICAL UNIVERSITY
Thyroid sodium/iodide symporter and nucleic acid encoding same
The present invention provides a purified and isolated nucleic acid encoding a sodium / iodide symporter. The present invention also provides purified sodium / iodide symporter, a vector comprising nucleic acid encoding sodium / iodide symporter, a host cell transformed with the vector, and a method for producing recombinant sodium / iodide symporter. In addition, the present invention provides nucleic acid probes and mixtures thereof specific for sodium / iodide symporter nucleic acid and antibodies immunoreactive with sodium / iodide symporter. The present invention also provides a method for diagnosing and treating thyroid disorders associated with non-functional sodium / iodide symporter. Furthermore, the present invention provides a method for the selective ablation of tissue. The present invention also provides a method for identifying an iodide transport protein in non-thyroid tissue. Finally, the present invention provides a non-human, transgenic model for a thyroid disorder.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Application of artemether to prevention and treatment of Alzheimer disease
InactiveCN109394757AImprove learning and memory abilityFunction increaseOrganic active ingredientsNervous disorderApoptosisClinical study
The invention discloses application of artemether to prevention and treatment of Alzheimer disease. The artemether is a safe and effective compound in anti-malaria treatment and activates an AMPK signal channel in the brain of an Alzheimer disease transgenic model mouse, the learning and memory ability of the Alzheimer disease transgenic model mouse is improved, apoptosis of nerve cells in the brain is reduced, the function of a choline acetyl transferase is improved, the activity of spongiocyte is inhibited, deposition of amyloid plaques, tangling of nerve fiber and the loss of nerve cells are reduced, and the experimental basis is provided for the clinical study for treating Alzheimer disease.
Owner:UNIVERSITY OF MACAU
Methods, compositions and transgenic models related to the interaction of t-cadherin and adiponectin
Disclosed are methods, compositions and transgenic models related to the interaction of T-cadherin and adiponectin.
Owner:SANFORD BURNHAM MEDICAL RES INST
Transferrin receptor transgenic models
In some aspects, the present invention provides chimeric transferrin receptor (TfR) polynucleotides and polypeptides. In other aspects, this invention provides chimeric TfR transgenic animal models and methods of using the animal models to identify therapeutics that can cross the blood-brain barrier.
Owner:DENALI THERAPEUTICS INC
Tricyclic pyrone compounds reduce amyloid beta aggregates
Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble Aβ species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular Aβ aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity.
Owner:KANSAS STATE UNIV RES FOUND +2
Application of compound in reducing protein accumulation for treating Alzheimer's Disease
InactiveCN108904488AInhibition of formation of Aβ amyloid depositsImprove learning and memory abilityOrganic active ingredientsNervous disorderBrain tissueAmyloid
The invention discloses an application of luteolin in antagonizing the accumulation of beta-amyloid protein, improving cognitive memory and reducing senile plaques. The Alzheimer's disease (AD) is a neurodegenerative disease characterized by neurofibrillary tangles, beta-amyloid (A beta) plaque deposition, and cognitive decline, The accumulation of extracellular toxicity of A beta protein is considered as one of the main links in the pathogenesis of AD. The luteolin can significantly inhibit the accumulation of beta-amyloid protein 1-42 monomers to form fibers, inhibits the formation of a betasecondary structure, and improves the spatial memory learning ability of AD mice and significantly eliminates amyloid plaques in the brain tissue of APP / PS1 double transgenic AD model mice. The luteolin can be applied to the treatment of Alzheimer's disease and related drug development.
Owner:NORTHEAST NORMAL UNIVERSITY
Construction method of a mouse model with conditional mTERT overexpression and application thereof
The invention provides a construction method of a mouse model with conditional mTERT overexpression and an application thereof. The construction method comprises the following steps: constructing a targeting vector through a seamless cloning technology, wherein the targeting vector comprises a 3.3 kb 5'homologous arm, a CAG promoter, loxp-stop-loxp, TERT-3XFlag-IRES-EGFP-WPRE-polyA and a 3.3 kb 3'homologous arm; cas9 mRNA, gRNA and the targeting vector are microinjected into fertilized eggs of wild type mice to obtain F0-generation mice, homologous recombination positive F0-generation mice are identified, F1-generation mice are obtained through breeding after backcross, and the F1-generation mice are conditional mTERT overexpressed mouse models. The mouse constructed by the construction method provided by the invention can mate with different Cre tool mice to realize specific overexpression in various tissues, organs and cell types of the whole body. The mouse can be used for modeling various transgenic models for researching embryo and nerve development, senescence, wound repair, tumor occurrence, development and treatment, and the mating of the mouse and a CreERT tool mouse can control the time of TERT overexpression through tamoxifen.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Dementia model transgenic mouse and screening method using thereof
Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.
Owner:KOREA INST OF SCI & TECH
Rapid screening method applied to model animal zebrafish transgenosis
InactiveCN107881200AImprove screening efficiencyHigh speedHydrolasesMicroinjection basedEarly juvenileScreening method
The invention provides a rapid screening method applied to model animal zebrafish transgenosis. The method includes the following steps of 1, building a gene expression vector containing a strong promoter, an objective gene and a label gene; 2, designing a specific target spot aiming at a target gene, and obtaining a targeted SgRNA sequence; 3, based on the specific target spot, building a homologous recombinant vector; 4, injecting a homologous recombinant vector section, mRNA obtained through in-vitro transcription synthesis of the SgRNA sequence and nCas9-mRNA obtained through in-vitro transcription synthesis together into a zebrafish zygote; 5, firstly, screening out zebrafishes lack of a target gene function, then conducting second screening through the label gene, obtaining a label gene expression individual, and therefore obtaining the expression individual which expresses the objective gene. Through the method, early juvenile zebrafishes can be screened, and the purpose of quickly establishing a transgenic model is achieved.
Owner:YANGZHOU UNIV
Tapasin-like protein
InactiveUS20020106664A1High expressionExtended half-lifeTesting eggsChemiluminescene/bioluminescenceCancer treatmentTapasin
The invention provides a cDNA which encodes tapasin-like protein. It also provides for the use of the cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.
Owner:INCYTE CORP
Transgenic non-human animal and uses thereof
InactiveUS20120255041A1Easy transitionReduce loss rateMicrobiological testing/measurementChemiluminescene/bioluminescenceWHOLE ANIMALHuman animal
The present invention relates generally to transgene constructs, transgenic non-human animals comprising transgene constructs, methods of making and methods of using the transgenic non-human animals comprising transgene constructs. An embodiment of the invention relates to methods of assaying the activation of GPCR ligands non-invasively in whole animals, tissue slices, or in native cells using a transgenic model containing a bioluminescent transgene reporter system that is responsive to pathway modulation following ligand binding of GPCR receptors.
Owner:SANOFI SA
Protein that modulates the stability of transcriptional regulatory complexes regulating nuclear hormone receptor activity, DNA encoding same, and antibodies thereto
InactiveUS20050119456A1Enhanced interactionAlters developmentPeptide/protein ingredientsReceptors for hormonesHematopoietic cellTransgenic Model
A gene in humans and mice, designated C21, encodes a family of proteins that play a role in transcriptional regulation. Two isoforms (α and β) produced by alternative splicing has been identified in humans. A transgenic model was created that shows that over-expression of C21 in mouse hematopoietic cells alters myeloid development and suggests that members of this family are involved in regulating stem cell differentiation. Over-expressing C21 in 3T3 fibroblasts increases their resistance to apoptotic stimuli. The C21 protein forms a complex with a class of molecules that plays a critical role in transcription, the co-repressors of nuclear hormone receptors.
Owner:NEW YORK UNIV
Transgenic model of alzheimer's disease
InactiveUS20130291135A1Improve the level ofImpaired amyloid clearanceGenetic engineeringFermentationAβ oligomersMicroglial cell activation
Evidence indicates dysregulation. of the immunoregulatory molecule CD45 occurs in Alzheimer's disease (AD). Transgenic mice overproducing amyloid-β peptide (Aβ) and deficient in CD45 (PSAPP / CD45− / −) recapitulate AD neuropathology. Increased cerebral intracellular and extracellular soluble oligomeric and insoluble Aβ, decreased plasma soluble Aβ increased microglial neurotoxic cytokines TNF-α and IL-1β, and neuronal loss were found in PSAPP / CD45− / − mice compared with CD45-sufficient PSAPP littermates. After CD45 ablation, in vitro and in vivo studies demonstrate a microglial phenotype whereby microglia phagocytose less Aβ but display proinflammatory properties. This microglial activation occurs with elevated Aβ oligomers and neural injury and loss as determined by decreased ratio of anti-apoptotic Bcl-xL to proapoptotic Bax, increased activated caspase-3, mitochondrial dysfunction, and loss of cortical neurons in PSAPP / CD45− / − mice. These data show that deficiency in CD45 activity leads to brain accumulation of neurotoxic Aβ oligomers and validate CD45-mediated microglial clearance of oligomeric Aβ as a novel AD therapeutic target.
Owner:UNIV OF SOUTH FLORIDA
Construction method and related vector of zebra fish heart specific expression model
ActiveCN108949756ADoes not introduce effects on developmentAccurate targetingStable introduction of DNAVector-based foreign material introductionExpression geneMultiple cloning site
The invention discloses a construction method and a related vector of a zebra fish heart specific expression model. A homologous recombinant vector comprises an insert fragment which is inserted withan initial vector and comprises a promoter of zebra fish heart specific expression, left and right homologous arms fused with LoxP site sequences, a polyclonal site, an internal ribosome entry site, areporter gene and a transcription termination fragment, wherein the promoter is positioned at the upstream of the reporter gene, and the termination signal is positioned at the downstream of the reporter gene; the left homologous arm is positioned at the upstream of the promoter, and the right homogenous arm is positioned at the downstream of the termination signal; the inner sides of the homologous arms contain LoxP sequences; the polyclonal site is positioned between the promoter and the reporter gene; and the left and right homologous arms are targeted to the zebra fish pigment gene. The invention further provides a construction method of the zebra fish heart specific expression model, which can be used for quickly establishing a transgenic model of the zebra fish heart specific expression gene, and regulating expression of the insert fragment.
Owner:YANGZHOU UNIV
Molecular method for changing flowering rhythm of petunia hybrida
The invention aims to provide a molecular method for regulating and controlling the flowering rhythm of petunia hybrida. In the implementation method of the molecular method, the molecular method forregulating and controlling the flowering rhythm of plants by using flower specific expression promoters and circadian clock genes together is realized in combination with the means of genetic transformation. The molecular method comprises the steps of promoter synthesis, LHY gene amplification and carrier construction, genetic transformation is carried out by using the important flower petunia hybrida with simple tissue and cell operation technology, short life cycle and clear genetic background as a transgenic model plant, and finally a transgenic plant of which the flowering time changes isobtained. The expression of the circadian clock gene LHY capable of regulating and controlling the flowering rhythm in petunia hybrida is promoted by the flower specific expression promoters, and theflowering time of the obtained transgenic plant is a new product with obvious difference compared with that of a contrast plant. Through the statistics of the flowering time of the obtained positive transgenic plant, the lowering time of the transgenic plant compared with that of a check plant is delayed by nearly four hours.
Owner:FUJIAN AGRI & FORESTRY UNIV
Application of triacetyl andrographolide as medicine for regulating degradation of autophagosome
PendingCN114028386AImprove learning and memory abilityReduce aggregationOrganic active ingredientsNervous disorderGene modelPhosphorylation
The invention belongs to the field of medicines, and relates to application of andrographolide, in particular to application of triacetyl andrographolide as a medicine for regulating autophagosome degradation. The invention relates to an application of triacetyl andrographolide in preparation of a medicine for promoting autophagosome clearance. The invention also discloses application of triacetyl andrographolide as a medicine for simultaneously reducing the expression levels of LC3-II and P62 in the brain. Triacetyl andrographolide also can be used as a medicine for reducing phosphorylation levels of Akt and mTOR, improving learning and improving memory. An APP / PS1 / Tau triple transgenic model mouse and an ApoE4 transgenic mouse are utilized to prove that the triacetyl andrographolide can effectively improve the learning and memory ability of a model animal and reduce the levels of A[beta]1-40 and A[beta]1-42 in the brain of a model animal. Triacetyl andrographolide can inhibit the activation of Akt-mTOR signals in both in-vivo and in-vitro models, relieve the excessive accumulation of LC3-II and P62, and reduce the aggregation of autophagosome.
Owner:HENAN UNIVERSITY
A method for constructing a zebrafish heart-specific expression model and related vectors
ActiveCN108949756BDoes not introduce effects on developmentAccurate targetStable introduction of DNAVector-based foreign material introductionBiotechnologyCloning Site
The invention discloses a method for constructing a zebrafish heart-specific expression model and related vectors. The homologous recombination vector includes an insert fragment inserted into the original vector. The insert fragment includes a zebrafish heart-specific expression promoter, a left homology arm and a right homology arm fused with the LoxP site sequence, a multiple cloning site, and internal ribose body entry site, reporter gene, and transcription termination signal fragment; wherein, the promoter is located upstream of the reporter gene, the termination signal is located downstream of the reporter gene, the left homology arm is located upstream of the promoter, and the right homology arm is located at the termination Downstream of the signal, the inner side of the homology arm contains the LoxP sequence, and the multiple cloning site is located between the promoter and the reporter gene; the left homology arm and the right homology arm target the zebrafish pigment gene. A method for constructing a zebrafish heart-specific expression model is also provided. The present invention can be used to quickly establish a transgenic model of zebrafish heart-specific expression genes, and at the same time, can regulate the expression of the inserted fragment.
Owner:YANGZHOU UNIV
A method for generating a ho-1/app/psen1 triple transgenic mouse model of Alzheimer's disease
ActiveCN105494263BFits a characteristic phenotypeOxidoreductasesFermentationDisease phenotypeGenetically modified mouse
Owner:HARBIN MEDICAL UNIVERSITY
Ankyrin repeat domain 2 protein variant
InactiveUS20020127636A1High expressionExtended half-lifeSugar derivativesMicrobiological testing/measurementDiseaseAnkyrin Repeat Protein
The invention provides a mammalian cDNA which encodes a mammalian Ankrd2V. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of muscle disorders such as muscle hypertrophy and particularly clear cell sarcoma. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.
Owner:INCYTE CORP
Application of artemisia annua extract in preparing preparation for treating or preventing AD
The invention discloses an application of an artemisia annua extract in preparing a preparation for treating or preventing AD. The artemisia annua boiled water extract can unexpectedly improve the learning and memory ability of Alzheimer's disease transgenic model mice, prevent nerve cell death caused by oxidative damage, promote mitochondrial transmembrane potential recovery, reduce amyloid plaque deposition, nerve fiber entanglement and neuron loss, and provides an experimental basis for clinical research on treatment of the AD.
Owner:UNIVERSITY OF MACAU
Transgenic model for delay-type hypersensitivity (DTH) and use thereof
Owner:MACAU UNIV OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com